U.S. Naloxone Market, by Drug Type (Branded and Generic), by Route of Administration (Intranasal Administration, Intramuscular Administration, Intravenous Administration, and others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and O

U.S. Naloxone Market, by Drug Type (Branded and Generic), by Route of Administration (Intranasal Administration, Intramuscular Administration, Intravenous Administration, and others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Naloxone is an opioid overdose reversal drug that has been licenced by the U.S. Food and Drug Administration (FDA). It is an opioid antagonist, which means it attaches to opioid receptors and can counteract and prevent the effects of opioids such as heroin, morphine, and oxycodone. Intranasal spray (into the nose), intramuscular (into the muscle), subcutaneous (under the skin), and intravenous injection are all options for administering the medicine. Naloxone is widely available over the counter at pharmacies in the U.S. as it is not prescribed medicine. Naloxone can also be obtained for free from community-based distribution initiatives, local public health groups, or local health departments.
Market Dynamics
Key players in the market are focused on adopting strategies such as partnerships, acquisitions, and programs to expand their product portfolio which is expected to drive the market growth. For instance, on October 22, 2021, Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced the donation of 50,000 vials of Naloxone HCl Injection, USP – a treatment for reversing opioid overdoses to members of the Opioid Safety and Naloxone Network (OSNN) Buyers Club to help ease an acute shortage of the medicine currently facing non-profit harm-reduction programs which includes treatments for HIV, hepatitis C virus (HCV), HBV counseling and testing, and naloxone for overdose in the U.S. the Opioid Safety and Naloxone Network (OSNN) is a network of over 100 harm-reduction programs in the U.S that distribute naloxone to drug users and their families. Some of its member programs have been participating in community naloxone distribution for over 20 years. Hikma's donation will come from its state-of-the-art sterile injectable manufacturing facility in Cherry Hill, New Jersey, and will be made in collaboration with Hikma Community Health, a new division of Hikma dedicated to providing a variety of treatment options for substance use disorder and opioid overdose in the U.S.
Key features of the study:
This report provides an in-depth analysis of the U.S. Naloxone market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. Naloxone market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
Key companies covered as a part of this study include Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. Naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the U.S. Naloxone market
Detailed Segmentation:
U.S. Naloxone Market, By Drug Type:
Branded
Generic
U.S. Naloxone Market, By Route of Administration:
Intranasal Administration
Intramuscular Administration
Intravenous Administration
Others
U.S. Naloxone Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Mylan N.V. *
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
Novartis AG
Indivior Plc.
ADAPT Pharma, Inc.
Amphastar Pharmaceuticals, Inc.
INSYS Therapeutics, Inc.
Mundipharma International Limited
Kaleo, Inc.
Kern Pharma, S.L
Samarth Life Sciences Pvt. Ltd.
Opiant Pharmaceuticals
Pfizer
Sandoz
Amneal Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.